Abstract
Osteoporosis is a major public health problem for adults above 55 years of age, which leads to an increase in bone fragility. Last decade has witnessed remarkable advances in molecular biology and genetics that led to detailed understanding of the bone remodeling cycle and new therapeutic targets for its treatment have emerged. Thus, besides classical approach (vitamin D and calcium administration, bisphosphonates, oestrogen, raloxifene), new therapeutic agents such as parathyroid hormone (PTH) compounds, anti-RANKL antibodies and strontium ranelate are or will be increasingly used in the treatment of osteoporosis. In this review, we have presented the importance and therapeutic potential of strontium ranelate as a dual agent in the current treatment of osteoporosis.
Keywords: Biological markers, Bone cells activity, Bone remodeling, Strontium Ranelate
Current Molecular Pharmacology
Title:Potential Anti-Catabolic and Anabolic Properties of Strontium Ranelate
Volume: 5
Author(s): Romuald Mentaverri, Michel Brazier, Said Kamel and Patrice Fardellone
Affiliation:
Keywords: Biological markers, Bone cells activity, Bone remodeling, Strontium Ranelate
Abstract: Osteoporosis is a major public health problem for adults above 55 years of age, which leads to an increase in bone fragility. Last decade has witnessed remarkable advances in molecular biology and genetics that led to detailed understanding of the bone remodeling cycle and new therapeutic targets for its treatment have emerged. Thus, besides classical approach (vitamin D and calcium administration, bisphosphonates, oestrogen, raloxifene), new therapeutic agents such as parathyroid hormone (PTH) compounds, anti-RANKL antibodies and strontium ranelate are or will be increasingly used in the treatment of osteoporosis. In this review, we have presented the importance and therapeutic potential of strontium ranelate as a dual agent in the current treatment of osteoporosis.
Export Options
About this article
Cite this article as:
Mentaverri Romuald, Brazier Michel, Kamel Said and Fardellone Patrice, Potential Anti-Catabolic and Anabolic Properties of Strontium Ranelate, Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020189
DOI https://dx.doi.org/10.2174/1874467211205020189 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Commentary ( Two Hits with One Shot – A Possibility of Simultaneous Targeting Motor Neuron Loss and Depression in ALS by Upregulating ADAR2 )
CNS & Neurological Disorders - Drug Targets Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Risk Factors of Burnout among Egyptian Medical Students: A Cross-sectional Study
Current Psychiatry Research and Reviews Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine Poly(ADP-Ribosyl)ation Enzyme-1 as a Target for Neuroprotection in Acute Central Nervous System Injury
Current Drug Targets - CNS & Neurological Disorders Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimers Disease
Current Pharmaceutical Design Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Hypothalamic AMP-activated Protein Kinase as a Regulator of Food Intake and Energy Balance
CNS & Neurological Disorders - Drug Targets A Novel Method to Predict Protein-Protein Interactions Based on the Information of Protein-Protein Interaction Networks and Protein Sequence
Protein & Peptide Letters Psychological Perspectives of Inflammatory Bowel Disease Patients Undergoing Surgery: Rightful Concerns and Preconceptions
Current Drug Targets Pharmacologic Considerations during the Preoperative Evaluation of Neurologic Patients
Current Clinical Pharmacology The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Brain Oxidative Stress - Analytical Chemistry and Thermodynamics of Glutathione and NADPH
Current Topics in Medicinal Chemistry